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 Abstract 
 Background: Extensive sets of data are required to investi-
gate the potential use of a therapeutic drug monitoring with 
individualization of dosage of the antimycotic compound 
caspofungin. The goal was to develop an improved liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) 
method for this aim. 
 Methods: Following protein precipitation, on-line solid 
phase extraction was performed for sample preparation. As 
the internal standard compound the veterinary drug tylosin 
was used. A standard validation protocol was applied. 
 Results: Good reproducibility and accuracy of the method 
were observed. On-line solid phase extraction resulted in a 
convenient work-fl ow and good robustness of the method. 
 Conclusions: This improved LC-MS/MS method was found 
reliable and convenient. It can be suggested for further work 
on the clinical pharmacology of caspofungin in the setting of 
clinical research laboratories. 
 Keywords:  caspofungin;  liquid chromatography-tandem 
mass spectrometry (LC-MS/MS);  on-line solid phase extrac-
tion (SPE); tylosin. 
 Invasive fungal infections represent a leading cause of mor-
bidity and mortality in immunocompromized patients today. 
During the last decade the therapeutic armamentarium has 
expanded substantially and now includes almost 10 com-
pounds to be considered for prophylaxis and treatment of 
invasive fungal infections  (1) . Therapeutic drug monitoring 
(TDM) is increasingly discussed for each of these drugs, 
however  – in contrast to immunosuppressants used in trans-
plantation medicine  – guidelines for TDM of anti-mycotic 
drugs have scarcely been defi ned or evaluated  (2) . 
 For the triazole compounds (itraconazol, posaconazol, vori-
conazol) chromatographic and mass spectrometric methods 
are now available in a substantial number of clinical research 
centers; the analytics of the more novel group of echinocan-
dines has been addressed only by a few groups so far. Among 
the echinocandines, on the one hand caspofungin plays the 
most important role in clinical practice to date, on the other 
hand a higher incidence of side-effects and potential for drug-
drug interactions is known for caspofungin  (3) . 
 Caspofungin steady-state concentrations in plasma between 
0.25 and 2.5  mg/L have been described for different admin-
istration regimens  (4) ; clinically relevant caspofungin levels 
range up to approximately 10  mg/L  (5) . 
 The aim of our work was to develop a reliable liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) 
method for respective clinical investigations, applicable in 
the setting of routine laboratories, thereby addressing some 
limitations of previously published methods (see online 
data Supplemental Appendix 1). Beyond published work on 
caspofungin measurement by LC-MS/MS two issues were 
addressed by our work in particular: investigation of a suited 
and commercially available compound for internal stan-
dardization and development of a semi-automated sample 
preparation protocol based on on-line solid phase extraction 
(SPE) prior to a standard LC-MS/MS system. This principle 
has been used in our laboratory for over 10  years now and is 
found to enable very robust methods with short run times and 
minimal down-times required for maintenance. 
 Twenty-fi ve microliters of calibrator, quality control sam-
ple, or serum was shortly vortexed with 50  μ L of phosphate 
buffered saline (PBS) solution in 1.5  mL polyproylene cups. 
Thereafter 75  μ L of internal standard (IS) working solution 
[approx. 100  μ g/L tylosin in acetonitrile/methanol (9:1 by 
volume)] was added. Cups were shaken for 10  min using a 
horizontal shaker. This was followed by centrifugation for 
10  min at 15,000  g . Ten microliters of each supernatant was 
injected into the LC-MS/MS system (Waters Alliance 2795 
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HPLC module; Waters, Milford, MA, USA), coupled split-
less to a Micromass Quattro Micro tandem mass spectrom-
etry system; mass spectrometric conditions are listed in the 
online data Supplemental Appendix 4. Sample clean-up was 
performed online using on-line SPE. 
 Supernatant was injected and loaded onto a Waters Oasis 
HLB column (2.1 × 20  mm; 25  μ m particle size; Waters, 
Milford, MA, USA) in valve position A (scheme of the on-
line SPE is given in Figure  1 ). The mobile phase was water/
methanol 90/10 (v/v), delivered at a fl ow rate of 4  mL/min. 
Potential interfering compounds were washed into waste. 
In parallel, the analytical column (xTerra C-8, 2.1 × 50  mm; 
3.5  μ m particle size; Waters, Milford, MA, USA) was equili-
brated with 70/30 (v/v) acetonitrile/15  mM ammonium for-
mate, delivered at a fl ow rate of 0.2  mL/min. After 1  min, 
the switching valve was changed to position B; the extraction 
column was now eluted in a back-fl ush mode onto the analyti-
cal column. After another 2  min, the valve was switched back 
to position A. During the analytical chromatography into the 
mass spectrometer in position A, the extraction column was 
washed for 1  min with 80/20 (v/v) methanol/1 % formic acid 
at a fl ow rate of 4  mL/min. The total run time was 3.5  min. 
 For quantifi cation, we applied 1/x fi t weighting of the peak 
area ratios of analyte/IS vs. the concentration to obtain the 
calibration curves. 
 Calibrators were made by diluting the working solution 
of caspofungin (see online data Supplemental Appendix 5) 
with drug-free human serum to obtain caspofungin concentra-
tions of 20.0, 10.0, 5.0, 2.5, 1.25, 0.62 and 0.31  mg/L. In the 
same manner, we prepared quality control samples in three 
concentration levels (16.0, 1.6 and 0.4  mg/L). We used one 
serum pool, in order to additionally study the imprecision 
of the method. This pool was prepared from residual serum 
sent for standard clinical chemistry analyses from patients, 
treated with caspofungin. Aliquots of quality control samples, 
calibrators and serum pool were stored in polypropylene vials 
at  – 80 ° C. 
 In 11 analytical series, applying full calibration, we dem-
onstrated mean accuracy ranged from 94.0 % to 97.3 % and 
coeffi cients of variation (CV) below 8 % (complete data is 
shown in online data Supplemental Appendix 2). The coef-
fi cient of determination of the seven calibrator samples was 
 > 0.99 (R 2 ) in all series (average y-intercept and slope values: 
y =1.01x − 0.03157). 
 Lower- and upper limit of quantifi cation (LLOQ, ULOQ) 
were assessed by analyzing different concentrations of 
spiked drug-free serum in duplicate in three runs. LLOQ was 
0.25  mg/L and ULOQ was 40  mg/L for caspofungin (crite-
rion for acceptance: accuracy of 80 % – 120 % , precision with 
a CV < 20 % ). 
 Specifi city of the method was demonstrated, when analyz-
ing 50 samples from residual serum of intensive care patients. 
None of the samples showed peaks in the multiple reaction 
monitoring (MRM) trace of caspofungin. 
 Ion-suppression characteristics of the method were assessed 
by connecting a T-piece between the chromatographic col-
umn and the ion source. Using a syringe pump, a pure solu-
tion of caspofungin (approx. 1  mg/L) and tylosin (0.1  mg/L) 
was delivered with a constant fl ow rate of 10  μ L/min into 
the T-piece. By this post-column infusion, a baseline offset 
was generated in the MRM-traces of caspofungin and tylo-
sin. At the respective retention times we did not observe any 
signifi cant variation of this offset upon injection of human 
serum samples, ruling out relevant ion suppression by resid-
ual matrix components. 
 To verify recovery of the method, aliquots of a serum pool, 
from patients treated with caspofungin, was spiked with dif-
ferent amounts of caspofungin working solution, resulting 
in fi ve different concentration ranges. Quantifi cation in the 
absence and presence of addition of caspofungin working 
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 Figure 1  (A) Scheme of the on-line solid phase extraction system (AC, analytical column; W, waste; MS, mass spectrometry system). (B) 
Representative MRM chromatograms obtained from a pooled serum sample (caspofungin approx. 2.5  mg/L). Upper panel: tylosin. Lower 
panel: caspofungin (retention time approx. 2.35  min); total run time: 3.5  min. Arrows indicate switching valve positions. 
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solution resulted in a mean recovery rate of 92.5 % (range: 
83.3 % – 99.3 % ). 
 Recovery of the two-step extraction process was evaluated. 
Samples in three concentration levels were analyzed with and 
without the on-line SPE procedure. A pure solution of caspo-
fungin in 20 % human serum albumin was directly injected 
onto the analytical column, by omitting the on-line SPE pro-
cedure, whereas spiked serum samples in the same concentra-
tion levels were submitted to the entire analytical process. A 
mean signal recovery of 111.7 % was found (n = 9). 
 Carry-over was evaluated by injecting the highest QC 
sample 10 times, immediately followed by a blank sample. 
The chromatogram of this sample was inspected for peaks in 
the MRM trace of caspofungin and resulted in a carry-over 
effect of  < 1 % . 
 Stability of precipitation extracts was evaluated by reanal-
ysis of deproteinized samples of a calibration series, 24  h after 
their initial analysis. Extracts obtained by protein precipita-
tion were found stable for at least 24  h  – a mean deviation of 
105.5 % of the peak areas of the MRM trace of caspofungin 
was noted (n = 6). 
 In this article a convenient LC-MS/MS method for quanti-
fi cation of caspofungin in serum is described; validation data 
characterize the method as applicable for clinical research 
use. Regarding previously described LC-MS/MS methods 
for the quantifi cation of caspofungin in blood, our method is 
novel with respect to the IS compound and with respect to 
a convenient semi-automated sample preparation protocol: 
in three of the previous methods  (6 – 8) an isoster of caspo-
fungin is used as the IS. This compound may be suited, but 
was obtained from the manufacturer of caspofungin and is 
not commercially available; thus the method cannot easily be 
reproduced. Decosterd et al.  (9) rely on stable isotope labeled 
voriconazole for internal standardization. This is questionable 
as well, since molecular weight and molecular structure of this 
compound is completely different from that of caspofungin. 
The compound tylosin, however, has a heterocyclic structure, 
as is the case for caspofungin, and a similar molecular weight 
(see online data Supplemental Appendix 3). It is commercially 
available and not in use in human medicine, but exclusively 
in veterinary medicine. Therefore, we considered tylosin to 
be a good candidate for use as IS; this was confi rmed by our 
validation results. Egle et al.  (10) completely abdicate the 
use of an IS, which is very uncommon in clinical mass spec-
trometry. Also, a complex and fully automated LC-ion trap 
MS method for caspofungin quantifi cation in serum, which 
requires two switching valves, two gradient HPLC pumps, a 
complicated chromatographic set-up and very extended chro-
matographic run times is described. In our experience, such 
application of crude serum to on-line extraction cartridges 
may be convenient but is hampered by the very limited life 
time of the extraction materials. Applying protein precipita-
tion prior to simple on-line SPE, an extended performance of 
the extraction columns and –  compared to direct analysis of 
deproteinized samples to HPLC  –  very good ionization effi -
cacy is guaranteed. 
 In agreement with previous articles, we identifi ed three 
particular problems for quantifi cation of caspofungin using 
LC-MS/MS: linearity of response over a wider calibration range 
 (6 – 8, 10) ; adsorption of the analyte to surfaces  (7, 11 – 13) ; and 
asymetrical peak shape due to isomers of the analyte  (8, 10) . 
Regarding linearity issues we found dilution with PBS nec-
essary to obtain acceptable calibration functions. Adsorption 
problems as carry-over issues should be addressed by rather 
long washing cycles and high proportions of organic solvents. 
Sub-optimum peak shape due to isomers (as demonstrated in 
Figure 1) requires consistent peak integration criteria. 
 In summary we suggest the use of tylosin as an IS together 
with on-line SPE after protein precipitation as an alternative 
for quantifi cation of caspofungin in blood using LC-MS/MS. 
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